Alimera Sciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALIM Nasdaq 2834 http://www.alimerasciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alimera Sciences Inc

Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates - Mar 31st, 2023 1:15 pm
Alimera Sciences Announces 2022 Financial Results and Business Update - Mar 31st, 2023 12:00 pm
Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility - Mar 27th, 2023 12:00 pm
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update - Mar 24th, 2023 8:05 pm
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors - Feb 27th, 2023 1:00 pm
Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN® - Feb 22nd, 2023 1:00 pm
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer - Jan 9th, 2023 1:00 pm
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript - Dec 29th, 2022 11:02 am
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement - Dec 8th, 2022 1:00 pm
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration - Nov 29th, 2022 1:00 pm
7 Stocks That Could Implode at Any Moment - Nov 17th, 2022 8:54 pm
Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations - Nov 16th, 2022 10:05 am
Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates - Nov 14th, 2022 1:55 pm
Alimera Sciences Announces Third Quarter 2022 Financial Results - Nov 14th, 2022 12:30 pm
Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update - Nov 2nd, 2022 12:00 pm
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic - Nov 1st, 2022 12:00 pm
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year? - Oct 20th, 2022 1:40 pm
10 Best Low Price Pharma Stocks To Buy Now - Oct 18th, 2022 1:03 pm
Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments - Oct 6th, 2022 12:00 pm
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network - Sep 23rd, 2022 12:00 pm